Completed PHASE4 INTERVENTIONAL 1-arm NCT01088724

Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) (FCD-R)

Sponsor: A.O. Ospedale Papa Giovanni XXIII

Conditions Non Burkitt Post-transplant Lymphoproliferative Disease (PTLD)

Interventions fludarabine, cyclophosphamide, doxorubicin, rituximab

Updated 5 times since 2017 Last updated: Mar 16, 2010 Started: Feb 28, 2002 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Non Burkitt and Post-transplant Lymphoproliferative Disease (PTLD) and is currently completed. A.O. Ospedale Papa Giovanni XXIII leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Feb 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

A.O. Ospedale Papa Giovanni XXIII

Data source: A.O. Ospedale Papa Giovanni XXIII

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bergamo, Italy